Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 60, Issue 4, Pages 1187-1195
Publisher
Wiley
Online
2014-07-28
DOI
10.1002/hep.27340
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010
- (2014) Maxine M. Denniston et al. ANNALS OF INTERNAL MEDICINE
- Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy
- (2013) C. Koh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cost Effectiveness of Direct-Acting Antiviral Therapy for Treatment-Naive Patients With Chronic HCV Genotype 1 Infection in the Veterans Health Administration
- (2013) Kee Chan et al. Clinical Gastroenterology and Hepatology
- Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort
- (2013) S. D. Holmberg et al. CLINICAL INFECTIOUS DISEASES
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
- (2013) Calogero Cammà et al. JOURNAL OF HEPATOLOGY
- Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus
- (2013) Juan Berenguer et al. JOURNAL OF HEPATOLOGY
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
- (2013) Christophe Hézode et al. JOURNAL OF HEPATOLOGY
- Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients
- (2013) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
- (2013) Adriaan J. van der Meer et al. JOURNAL OF HEPATOLOGY
- The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010
- (2013) Ivo Ditah et al. JOURNAL OF HEPATOLOGY
- All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses
- (2013) L. M. Hagan et al. JOURNAL OF VIRAL HEPATITIS
- Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients
- (2013) Antonio Blázquez-Pérez et al. PHARMACOECONOMICS
- Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients
- (2013) Sandrine Cure et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal
- (2013) Elamin H. Elbasha et al. Applied Health Economics and Health Policy
- Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients
- (2012) A. S. Rangnekar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin
- (2012) Y. Chen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The high comorbidity burden of the hepatitis C virus infected population in the United States
- (2012) Karly S Louie et al. BMC INFECTIOUS DISEASES
- Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
- (2012) Fred Poordad et al. GASTROENTEROLOGY
- Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
- (2012) Calogero Cammà et al. HEPATOLOGY
- Chronic hepatitis C virus (HCV) disease burden and cost in the United States
- (2012) Homie Razavi et al. HEPATOLOGY
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy
- (2012) Stella M. Martinez et al. PLoS One
- Economic Burden Associated With Patients Diagnosed With Hepatitis C
- (2011) Jeffrey S. McCombs et al. CLINICAL THERAPEUTICS
- Hepatitis C virus infection in USA: an estimate of true prevalence
- (2011) Eric Chak et al. LIVER INTERNATIONAL
- Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
- (2011) Kenneth E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study
- (2010) Savino Bruno et al. HEPATOLOGY
- Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population
- (2010) Keith L. Davis et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Role of simple biomarkers in predicting fibrosis progression in HCV infection
- (2010) Rajasekhara R Mummadi WORLD JOURNAL OF GASTROENTEROLOGY
- A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus
- (2009) Amit G. Singal et al. Clinical Gastroenterology and Hepatology
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
- (2009) Gary L. Davis et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started